105 related articles for article (PubMed ID: 8851121)
1. [Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system].
Maass JD; Gottschlich S; Lippert BM; Niemann AM; Görögh T; Werner JA
Laryngorhinootologie; 1996 Jan; 75(1):53-6. PubMed ID: 8851121
[TBL] [Abstract][Full Text] [Related]
2. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma--five years survival rate].
Hofele C; Schwager-Schmitt M; Volkmann M
Laryngorhinootologie; 2002 May; 81(5):342-5. PubMed ID: 12001023
[TBL] [Abstract][Full Text] [Related]
4. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
5. [Immune response to p53 protein in patients with squamous epithelial carcinoma of the upper aerodigestive tract is independent of p53 point mutation].
Gottschlich S; Maass JD; Görögh T; Lippert BM; Werner JA
Laryngorhinootologie; 1996 May; 75(5):301-5. PubMed ID: 8672215
[TBL] [Abstract][Full Text] [Related]
6. Head and neck cancer and p53-immunogenicity.
Maass JD; Gottschlich S; Goeroegh T; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2873-4. PubMed ID: 9329551
[TBL] [Abstract][Full Text] [Related]
7. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
8. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
9. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
[TBL] [Abstract][Full Text] [Related]
10. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
11. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
12. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
14. High rate of p53 overexpression in head and neck carcinomas detected with a refined ELISA.
Maass JD; Gottschlich S; Goeroegh T; Bruhn T; Lippert BM; Paulsen JI; Werner JA
Anticancer Res; 1997; 17(1A):473-8. PubMed ID: 9066697
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
[TBL] [Abstract][Full Text] [Related]
17. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
19. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
20. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
